Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III

Peptides

Volumn 25, Issue 4, 2004, Pages 659-666

  Pelleymounter, Mary Ann ^a,b   Joppa, Margaret ^a   Ling, Nick ^a   Foster, Alan C ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

ACTH; Anxiety; Corticotropin releasing factor (CRF); Elevated plus maze (EPM); Food Intake; Human urocortin III (hUcn III); Mouse urocortin II (mUcn II); Stress

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; HORMONE RECEPTOR; UROCORTIN;

ANIMAL EXPERIMENT; ANOREXIA; ARTICLE; BEHAVIOR; FEMALE; FOOD INTAKE; HORMONE RELEASE; MALE; MAZE TEST; MOUSE; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; STRESS;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANXIETY; CORTICOTROPIN-RELEASING HORMONE; EATING; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS;

EID: 2542440528     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2004.01.008     Document Type: Article

References (41)

1. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behavior and are hypersensitive to stress. Nat. Genet. 24:2000;410-414
2. Bale T.L., Picetti R., Contarino A., Koob G.F., Vale W.W., Lee K.F. Mice deficient for both corticotropin-releasing factor receptor-1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J. Neurosci. 22:2002;193-199
3. 1 receptor mRNA expression. J. Neurosci. 15:1995;6340-6350
4. Cohen R.M., Kang A., Gulick C. Quantitative trait loci affecting the behavior of A/J and CBA/J intercross mice in the elevated plus maze. Mamm. Genome. 12:2001;501-507
5. Contarino A., Dellu F., Koob G., Smith G., Lee K-F., Vale W., et al. Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice. Endocrinology. 41:2000;2698-2702
6. Conti L.H., Costello D.G., Martin L.A., White M.F., Abreu M.E. Mouse strain differences in the behavioral effects of corticotropin-releasing factor (CRF) and the CRF antagonist alpha-helical CRF9-41. Pharmacol. Biochem. Behav. 48:1994;497-503
7. Coste S.C., Kesterson R.A., Heldwin K.A., Stevens S.L., Heard A.D., Hollis J.H., et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat. Genet. 24:2000;403-409
8. Cullen M.J., Ling N., Foster A.C., Pelleymounter M.A. Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology. 14:2001;992-999
9. File S. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res. 125:2001;151-157
10. 1 receptor antagonist II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345
11. Hammack S.E., Schmid M.J., LoPresti M.L., Der-Avakian A., Pelleymounter M.A., Foster A.C., et al. Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J. Neurosci. 23:2003;1019-1025
12. Higelin J., Py-Lang G., Paternoster C., Ellis G., Patel A., Dautzenberg F. 125I-antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin releasing factor type 2 receptors. Neuropharmacology. 40:2001;114-122
13. Ho S.P., Takahashi L.K., Livanov V., Spencer K., Lesher T., Maciag C., et al. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Mol. Brain Res. 89:2001;29-40
14. Hsu S.Y., Hsueh A.J.W. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2-corticotropin-releasing hormone receptor. Nat. Med. 7:2001;1-7
15. Inoue K., Valdez G.R., Reyes T.M., Reinhardt L.E., Tabarin A., Rivier J., et al. Human Ucn II, a selective agonist for the Type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat. J Pharmacol. Exp. Ther. 305:2003;385-393
16. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., et al. Deletion of the Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat. Genet. 24:2000;415-419
17. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98:2001;7570-7575
18. Li C., Vaughan J., Sawchenko P.E., Vale W.W. Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of Type 2 corticotropin-releasing factor receptor expression. J. Neurosci. 22:2002;991-1001
19. Moreau J.L., Kilpatrick G., Jenck F. Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport. 8:1997;1697-1701
20. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S-I., Nakazato A., et al. Receptor binding, behavioral and electrophysiological profiles of nonpeptide corticotropin releasing factor subtype I receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 289:1999;926-935
21. Pelleymounter M.A., Joppa M., Carmouche M., Cullen M.J., Brown B., Murphy B., et al. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J. Pharmacol. Exp. Ther. 293:2000;799-806
22. 2 receptors in behavioral, but not endocrine, response to environmental stress. J. Pharmacol. Exp. Ther. 302:2002;145-152
23. Pellow S., Chopin P., File S., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167
24. Preil J., Muller M.B., Gesing A., Reul J.M.H.M., Sillaber I., Van Gaalen M.M., et al. Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2. Endocrinology. 142:2001;4946-4955
25. Radulovic J., Ruhmann A., Liepold T., Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J. Neurosci. 19:1999;5016-5025
26. Ramos A., Berton O., Mormede P., Chaouloff F. A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behav. Brain Res. 85:1997;57-69
27. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98:2001;2843-2848
28. Ruhmann A., Bonk I., Lin C.R., Rosenfeld M.G., Spiess J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2B-selective antisauvagine-30. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15264-15269
29. Slawecki C.J., Somes J.C., Rivier C., Ehlers C.L. Neurophysiological effects of intracerebroventricular administration of urocortin. Peptides. 20:1999;211-218
30. Smagin G.N., Howell L.A., Ryan D.H., DeSouza E.B., Harris R.B. The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia. Neuroreport. 9:1998;1601-1606
31. Smith G.W., Aubry J-M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response and aberrant neuroendocrine development. Neuron. 20:1998;1093-1102
32. Sajdyk T.J., Gehlert D.R. Astressin, a corticotropin-releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala. Brain Res. 877:2000;226-234
33. Spina M., Merlo-Pich E., Chan R.D.W., Basso A.M., Rivier J., Vale W., et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science. 273:1996;1561-1564
34. Spina M.G., Merlo-Pich E., Akwa Y., Balducci C., Basso A.M., Zorrilla E.P., et al. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology. 160:2002;113-121
35. Sudakov S.K., Medvedeva O.F., Rusakova I.V., Terebilina N.N., Goldberg S.R. Differences in genetic predisposition to high anxiety in two inbred rat strains: role of substance P, diazepam binding inhibitor fragment and neuropeptide Y. Psycopharmacology. 154:2001;327-335
36. Takahashi L., Ho S., Livanov V., Graciani N., Arneric N.S. Antagonism of CRF2 receptors produces anxiolytic behavior in animal models of anxiety. Brain Res. 902:2001;135-142
37. Vale W.W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397
38. Valdez G.R., Inoue K., Koob G.F., Rivier J., Vale W., Zorrilla E.P. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res. 943:2002;142-150
39. Valdez G.R., Zorilla E.P., Rivier J., Vale W.W., Koob G.F. Locomotor suppressive and anxiolytic-like effects of urocortin-3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res. 980:2003;206-212
40. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., et al. Urocortin, a mammalian neuropeptide related fish urotensin I and to corticotropin-releasing factor. Nature. 378:1995;287-292
41. Vetter DE, Li C, Zhao L, Contarino A, Liberman MC, Smith GW, et al. Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat Genet 2002;1-7 [advanced online publication].